TGA Approval Marks a Global Breakthrough for Longevity Science
Longevity Life Sciences (LLS) is honoured to announce that Nicotinamide Mononucleotide (NMN) has been formally added to the Therapeutic Goods Administration (TGA) Permissible Ingredients Determination — making Australia the first country in the world to officially approve NMN for use in therapeutic goods.
This landmark regulatory decision represents a defining moment for the field of longevity medicine. It establishes Australia as the global leader in setting a rigorous, pharmaceutical-grade framework for NMN — a distinction unmatched by any other jurisdiction to date.
LLS: The Only Company Permitted to Supply NMN for Human Consumption in Australia
Following this decision, LLS is currently the only authorised supplier of NMN for human consumption in Australia via our flagship ingredient, CellVive NMN™.
This outcome reflects years of scientific collaboration, regulatory engagement, and our commitment to building the highest standards of evidence-based longevity innovation.
Why This Matters
- The world’s first regulated, therapeutic-grade access pathway for NMN
- Legally compliant, transparent supply for Australian consumers
- Pharmaceutical-grade quality, purity, and manufacturing standards
- Evidence-aligned claims under TGA oversight
Australia Sets the Global Benchmark
With this approval, Australia becomes the first country globally to formally recognise and regulate NMN within a therapeutic framework.
Canada has taken steps toward regulating NMN within natural health products — however, Australia is the first to enshrine NMN within a therapeutic, pharmaceutical-grade category.
This milestone validates the rigorous scientific, regulatory and manufacturing foundations LLS has established in partnership with SyncoZymes in Shanghai, global leaders in enzymatically synthesised, high-purity NMN.
A New Chapter for Evidence-Based Longevity Innovation
With NMN now permissible for inclusion in listed medicines, CellVive NMN™ becomes the benchmark for:
- Regulated NMN supply
- High-purity NAD⁺ restoration ingredients
- Guiding future clinical research and therapeutic development
- Responsible innovation grounded in science and safety
Co-founders Sally Panton and Lucy Canny emphasise that this milestone is both a validation of the work to date and the beginning of a new era for longevity therapeutics. For the first time, consumers, researchers and global partners can access NMN in a regulated, clinically credible framework.
LLS looks forward to supporting Australian brands, healthcare partners and research institutions as the next generation of longevity therapeutics takes shape.
For media or partnership enquiries, please contact: enquiries@longevitylifesciences.com
